Lv1
40 积分 2022-10-10 加入
流行病学/肿瘤学
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
2天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
11个月前
已完结
Management of locally advanced non‐small cell lung cancer: state of the art and future directions
1年前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
2年前
已完结
Response to Letter to the Editor Titled “Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?”
3年前
已完结
皖公网安备34019202002308
